How to Solve the Production Challenges of AAVs for Gene Therapy

CEVEC Pharmaceuticals has found a solution and developed a platform that can produce adeno-associated viral vectors (AAVs) as easily as if they were monoclonal antibodies.

Labiotech, June 3, 2020

Read the interview with Nicole Faust, CEO of CEVEC


Subscribe for the CEVEC Newsletter according to our Privacy Policy to receive the latest CEVEC News, including Press Releases, Conference Information and Webinar Invitations.

© CEVEC Pharmaceuticals GmbH 2020